{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T05:55:42Z","timestamp":1790920542087,"version":"4.1.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>CD20\u00d7CD3 bispecific antibodies are associated with acute immune-effector toxicities and infections, but drug-specific postmarketing co-reporting and report-level onset patterns remain incompletely characterized in B-cell lymphoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a label-anchored FAERS pharmacovigilance analysis with descriptive JADER contextualization. Deduplicated FAERS reports from 2022 Q4 through 2026 Q1 were restricted to primary-suspect epcoritamab, glofitamab, or mosunetuzumab reports in B-cell lymphoma, yielding 2,879 exposed reports. Prespecified MedDRA endpoints were evaluated against a disease-restricted comparator. Primary adjusted reporting odds ratios (aRORs) accounted for demographics, disease subgroup, reporting region, and calendar year. We mapped report-level phenotype intersections, summarized time to onset (TTO), and performed model-specification, restriction, comparator-exclusion, and TTO-completeness analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cohort included 1,463 epcoritamab, 944 glofitamab, and 472 mosunetuzumab reports. CRS had higher primary adjusted reporting odds for epcoritamab (aROR 4.70, 95% CI 4.15 to 5.32), glofitamab (3.43, 2.94 to 4.00), and mosunetuzumab (6.23, 4.97 to 7.81). ICANS had higher reporting odds for epcoritamab (2.28, 1.87 to 2.80); the glofitamab estimate crossed 1 in the primary model (1.26, 0.93 to 1.70) and varied with covariate specification, while mosunetuzumab ICANS was sparse. Epcoritamab had higher reporting odds for CMV (4.54, 3.66 to 5.62) and narrow opportunistic infection (2.20, 1.84 to 2.63). Mosunetuzumab had higher reporting odds for pneumonia\/lower respiratory infection (1.74, 1.32 to 2.31) and COVID-19 (1.66, 1.25 to 2.21), although these infection-specific patterns attenuated in some geographic and calendar restrictions. Immune-effector and infectious phenotypes co-occurred in reports containing serious outcomes. TTO was calculable for 33.7%\u201361.2% of reports and suggested earlier CRS than infection-associated reporting, but report characteristics differed by TTO completeness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CRS was the clearest shared reporting pattern across the three CD20\u00d7CD3 antibodies. Neurotoxicity and infection-associated findings were more drug- and analysis-dependent. Report-level co-reporting supports concurrent consideration of inflammatory toxicity and infection when presentations overlap, while later infection-associated TTO distributions support continued awareness beyond step-up dosing. Spontaneous-reporting data cannot estimate incidence, causality, or comparative treatment risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1920122","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T05:37:55Z","timestamp":1790919475000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune-effector and infection-associated reporting patterns of CD20\u00d7CD3 bispecific antibodies in B-cell lymphoma: a label-anchored FAERS analysis with descriptive JADER contextualization"],"prefix":"10.3389","volume":"17","author":[{"given":"Hao","family":"Zhong","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Third Affiliated Hospital of Sun Yat-sen University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjian","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Huizhou Central People\u2019s Hospital","place":["Huizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanduan","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Third Affiliated Hospital of Sun Yat-sen University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Third Affiliated Hospital of Sun Yat-sen University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guihao","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Third Affiliated Hospital of Sun Yat-sen University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies \u2014 BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00521-4","article-title":"T-cell-engaging bispecific antibodies in cancer","volume":"402","author":"Van De Donk","year":"2023","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell\u2013engaging antibody, in relapsed or refractory large B-cell lymphoma: Dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"JCO"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00166-2","article-title":"Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study","volume":"11","author":"Linton","year":"2024","journal-title":"Lancet Haematology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01774-4","article-title":"Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial","volume":"404","author":"Abramson","year":"2024","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009260","article-title":"Mosunetuzumab monotherapy is active and tolerable in patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"7","author":"Bartlett","year":"2023","journal-title":"Blood Adv"},{"key":"B9","unstructured":"EPKINLY (Epcoritamab-Bysp) Prescribing Information\n          \n          2026"},{"key":"B10","unstructured":"COLUMVI (Glofitamab-Gxbm) Prescribing Information\n          \n          2026"},{"key":"B11","unstructured":"LUNSUMIO (Mosunetuzumab-Axgb) Prescribing Information\n          \n          2026"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022432","article-title":"Consensus recommendations on the management of toxicity associated with CD3\u00d7CD20 bispecific antibody therapy","volume":"143","author":"Crombie","year":"2024","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114075","article-title":"Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review","volume":"205","author":"G\u00e9raud","year":"2024","journal-title":"Eur J Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025017366","article-title":"Infections after bispecific antibodies in B-cell lymphomas","volume":"10","author":"Kim","year":"2026","journal-title":"Blood Adv"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2025.2540442","article-title":"Real-world infectious complications of CD3\/CD20 bispecific antibodies in relapsed\/refractory non-Hodgkin lymphoma","volume":"66","author":"Xiao","year":"2025","journal-title":"Leukemia Lymphoma"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016291","article-title":"Comparative infection risk in CAR T vs bispecific antibodies in B-cell lymphoma: a systematic review and meta-analysis","volume":"9","author":"Van Besien","year":"2025","journal-title":"Blood Adv"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B18","doi-asserted-by":"publisher","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1016\/j.clinthera.2018.07.012","article-title":"Pharmacovigilance: an overview","volume":"40","author":"Beninger","year":"2018","journal-title":"Clin Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2020.02.022","article-title":"Uses of pharmacovigilance databases: An overview","volume":"75","author":"Bihan","year":"2020","journal-title":"Therapies"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1593405","article-title":"The silent signals: Emerging safety concerns in bispecific antibody therapy for multiple myeloma","volume":"12","author":"Zhou","year":"2025","journal-title":"Front Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1740144","article-title":"Real-world safety profile of T-cell engagers: Evidence from multi-database analysis with CAR-T comparisons","volume":"17","author":"Zhong","year":"2026","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13045-026-01809-3","article-title":"Cardiovascular adverse events associated with bispecific antibodies in relapsed or refractory B-cell non-Hodgkin lymphomas","volume":"19","author":"Munir","year":"2026","journal-title":"J Hematol Oncol"},{"key":"B24","unstructured":"FDA Adverse Event Reporting System (FAERS) Public Dashboard and Quarterly Data Files"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4944","article-title":"Quality evaluation of the Japanese Adverse Drug Event Report database (JADER)","volume":"29","author":"Tsuchiya","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200730070-00009","article-title":"Standardised MedDRA Queries: Their role in signal detection","volume":"30","author":"Mozzicato","year":"2007","journal-title":"Drug Saf"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-024-01421-9","article-title":"The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): Development and statement","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-024-01423-7","article-title":"The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): Explanation and elaboration","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"B30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"Van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200023060-00004","article-title":"A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO International Database","volume":"23","author":"Lindquist","year":"2000","journal-title":"Drug Saf"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1080\/00031305.1999.10474456","article-title":"Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system","volume":"53","author":"Dumouchel","year":"1999","journal-title":"Am Stat"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.285245","article-title":"Bispecific antibodies in follicular lymphoma","volume":"110","author":"Nizamuddin","year":"2025","journal-title":"Haematol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.03.048","article-title":"Non-relapse mortality with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma","volume":"33","author":"Tix","year":"2025","journal-title":"Mol Ther"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae460","article-title":"Disseminated Mycobacterium avium complex infection following CD3\/CD20 bispecific antibody therapy in a patient with follicular lymphoma","volume":"11","author":"Little","year":"2024","journal-title":"Open Forum Infect Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1920122\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T05:37:56Z","timestamp":1790919476000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1920122\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":36,"alternative-id":["10.3389\/fimmu.2026.1920122"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1920122","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"article-number":"1920122"}}